 beta blocker use.
Similarly, although there is currently no Level 1 evidence
to inform on the efÔ¨Åcacy of statins among patients undergoing CAS, individual case series support this
approach. For example, in a series of 180 patients undergoing CAS, the 30-day risk of stroke, death, and MI was
4% among statin users vs 15% among nonusers (P <
.05).94 In another series of 3